Drugs / SYS6041
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07714668 | Aug 2026 → Apr 2028 expected | ovarian cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-04-14 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SYS6041 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗
The board of directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ‘‘, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that the Investigational New Drug (IND) application for SYS6041 (Antibody-Drug Conjugate) ( the ‘‘Product ’’) developed by the Group has been approved by the U.S. Food and Drug Administration (F DA) to conduct clinical trials in the United States. |
| 2025-01-10 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SYS6041 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-31 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYS6041 AS A COMBINATION THERAPY FOR THE TREATMENT OF RECURRENT OVARIAN CANCER OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA irasia.com ↗ |
| 2025-04-14 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - SYS6041 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗ |
| 2025-01-10 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - SYS6041 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYS6041 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07714668 ↗ |
| Route | Intravenous | “SYS6041: RP2D dose, ivgtt, Q3W” NCT07714668 ↗ |